



PATENT
ATTORNEY DOCKET NO. 50164/022002

Certificate of Mailing: Date of Deposit: August 29, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Elvis De la Cruz
Printed name of person mailing correspondence

[Signature]
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Alexis Borisy et al.	Art Unit:	1614
Serial No.:	10/617,424	Examiner:	Kevin Weddington
Filed:	July 11, 2003	Customer No.:	21559
Title:	COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after the mailing of a first Office action on the merits,

09/01/2005 CNGUYEN2 00000014 10617424

01 FC:1806


180.00 OP

but before the mailing of a final Office action or a Notice of Allowance. A check for \$180.00 in payment of the late submission fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.


Respectfully submitted,

Date: 8/29/05



Paul T. Clark
Reg. No. 30,162

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



Reg. No. 52,608



SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50164/022002		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. §1.98(b))		Serial No.		10/617,424		
		Applicant		Alexis Borisy et al.		
		Filing Date		July 11, 2003		
		Group		1614		
		IDS Filed		August 29, 2005		
		Customer No.		21559		
U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Issue/ Publication Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	5,104,858	04/14/92	Hait et al.			
	5,428,051	06/27/95	Tidwell et al.			
	5,443,962	08/22/95	Draetta et al.			
	5,521,189	05/28/96	Boykin et al.			
	5,602,172	02/11/97	Boykin et al.			
	5,643,935	07/01/97	Dykstra et al.			
	5,723,495	03/03/98	Hall et al.			
	5,770,585	06/23/98	Kaufman et al.			
	5,843,980	12/01/98	Hall et al.			
	6,008,247	12/28/99	Boykin et al.			
	6,025,398	02/15/00	Hall et al.			
	6,172,104	01/09/01	Tidwell et al.			
	6,214,883	04/10/01	Hall et al.			
	6,280,768	08/28/01	McDevitt			
	6,326,395	12/04/01	Tidwell et al.			
	6,642,221	11/04/03	Uckun et al.			
	6,693,125	02/17/04	Borisy et al.			
	2003-0114703	06/19/03	Leblanc et al.			
	2003-0144338	07/31/03	Matsumoto et al.			
	2003-0161893	08/28/03	Yi			
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50164/022002 Serial No. 10/617,424 Applicant Alexis Borisy et al. Filing Date July 11, 2003 Group 1614 IDS Filed August 29, 2005 Customer No. 21559		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)						
(37 C.F.R. §1.98(b))						
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATIONS						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 99/46237	09/16/99	WIPO			
	WO 01/35935	05/25/01	WIPO			
	1,288,376	09/06/72	Great Britain			
	CH 681780	05/28/93	Switzerland			Yes
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
Aftab et al., "Structure-activity Relationships of Phenothiazines and Related Drugs for Inhibition of Protein Kinase C," <i>Mol. Pharmacol.</i> 40:798-805 (1991).						
Akiyama et al., "Circumvention of Multiple-Drug Resistance in Human Cancer Cells by Thioridazine, Trifluoperazine, and Chlorpromazine," <i>J. Natl. Cancer Inst.</i> 76:839-844 (1986).						
Al-Abdely et al., "Efficacies of KY62 Against <i>Leishmania amazonensis</i> and <i>Leishmania donovani</i> in Experimental Murine Cutaneous Leishmaniasis and Visceral Leishmaniasis," <i>Antimicrob. Agents Chemother.</i> 42:2542-2548 (1998).						
Andres et al., "Biochemical Effects of Chlorpromazine on Mouse Neuroblastoma Cells," <i>Vet. Hum. Toxicol.</i> 41:273-278 (1999).						
Anees et al., "Inhibition of a Tumor Protease with 3,4-Dichloroisocoumarin, Pentamidine-Isethionate and Guanidino Derivatives," <i>J. Enzyme Inhib.</i> 8:213-221 (1994).						
Bailly et al., "Sequence-Selective Binding to DNA of bis(amidinophenoxy) Alkanes Related to Propamidine and Pentamidine," <i>Biochem. J.</i> 323:23-31 (1997).						
Bailly et al., "Sequence-Specific DNA Minor Groove Binders. Design and Synthesis of Netropsin and Distamycin Analogues," <i>Bioconjug. Chem.</i> 9:513-538 (1998).						
Barak et al., "The Effect of Chlorpromazine and Haloperidol on DNA Transcription," <i>Int. Clin. Psychopharmacol.</i> 11:193-197 (1996).						
Barancik et al., "Reversal effects of Several Ca ²⁺ Entry Blockers, Neuroleptics and Local Anesthetics on P-Glycoprotein Mediated Vincristine Resistance of L1210/VCR Mouse Leukaemic Cell Line," <i>Drugs Exptl. Clin. Res.</i> 20:13-18 (1994).						
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50164/022002
				Serial No.	10/617,424
				Applicant	Alexis Borisy et al.
				Filing Date	July 11, 2003
				Group	1614
				IDS Filed	August 29, 2005
				Customer No.	21559
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)					
(37 C.F.R. §1.98(b))					
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)					
	Barrett et al., "Anti-Sleeping Sickness Drugs and Cancer Chemotherapy," <i>Parasitol. Today</i> 16:7-9 (2000).				
	Bebawy et al., "Selective Modulation of P-Glycoprotein-Mediated Drug Resistance," <i>Brit J. Cancer</i> 85:1998-2003 (2001).				
	Beckett et al., "Metabolism of Chlorpromazine and Promazine in vitro: Isolation and Characterization of N-Oxidation Products," <i>Xenobiotica</i> 18:61-74 (1988).				
	Bell et al., "Structure-activity Relationships of Pentamidine Analogs Against <i>Giardia lamblia</i> and Correlation of Antigiardial Activity with DNA-Binding Affinity," <i>Antimicrob. Agents Chemother.</i> 35:1099-1107 (1991).				
	Benaim et al., "A Calmodulin-Stimulated Ca ²⁺ Pump in Plasma-Membrane Vesicles from <i>Trypanosoma brucei</i> ; Selective Inhibition by Pentamidine," <i>Biochem. J.</i> 296:759-763 (1993).				
	Bleeker et al., "The Effects of Dexamethazone and Chlorpromazine on Tumor Necrosis Factor-Alpha, Interleukin-1 Beta, Interleukin-1 Receptor Antagonist and Interleukin-10 in Human Volunteers," <i>Immunology</i> 91:548-552 (1997).				
	Bornstein et al., "An Evaluation of the Mechanism of Action of Pentamidine Isethionate," <i>J. Surg. Oncol.</i> 2:393-398 (1970).				
	Borsa et al., "Selective Cytotoxicity of Calmidazolium and Trifluoperazine For Cycling Verses Noncycling C3H10T1/2 cells In Vitro," <i>Cancer Res.</i> 46:133-136 (1986).				
	Chen et al., "Anti-Tumor Necrosis Factor Properties of Non-Peptide Drugs in Acute-Phase Responses," <i>Eur. J. Pharmacol.</i> 271:319-327 (1994).				
	Clancy et al., "Chlorpromazine Modulates Cytokine Expression in the Liver and Lung After Burn Injury and Endotoxemia," <i>J. Trauma</i> 48:215-223 (2000).				
	Corsini et al., "Induction of Tumor Necrosis Factor-Alpha In Vivo by a Skin Irritant, Tributyltin, Through Activation of Transcription Factors: Its Pharmacological Modulation by Anti-Inflammatory Drugs," <i>J. Invest. Dermatol.</i> 108: 892-896 (1997).				
	Cresson et al., "In Vitro Inhibition of Human Sarcoma Cells' Invasive Ability by Bis(5-Amidino-2-Benzimidazolyl) Methane-a novel esterolprotease inhibitor," <i>Am. J. Pathol.</i> 123:46-56 (1986).				
	Cubria et al., "Aromatic Diamidines are Reversible Inhibitors of Porcine Kidney Diamine Oxidase," <i>Biochem. Pharmacol.</i> 45:1355-1357 (1993).				
	Darkin et al., "Chlorpromazine: A Potential Anticancer Agent?," <i>Biochem. Biophys. Res. Commun.</i> 125:184-191 (1984).				
EXAMINER			DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.					

SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. §1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed Customer No.	50164/022002 10/617,424 Alexis Borisy et al. July 11, 2003 1614 August 29, 2005 21559
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)			
Dautzenberg et al., "Pentamidine Aerosol in the Preventive Treatment of Pneumocystosis in AIDS Patients. Comparison of Two Salts and Two Nebulizers," <i>Presse Med.</i> 20: 1117-1120 (1991). (Abstract in English)			
Del Poeta et al., "Structure-In Vitro Activity Relationships of Pentamidine Analogues and Dication-Substituted Bis-Benzimidazoles as New Antifungal Agents," <i>Antimicrob. Agents Chemother.</i> 42:2495-2502 (1998).			
Driscoll et al., "Pyschotropic Drugs as Potential Antitumor Agents: A Selective Screening Study," <i>Cancer Treatment Rep.</i> 62:45-74 (1978).			
Ferroni et al., "N ₁ -Substituted Benzamidines: Synthesis, Antiproteinase Activity and Inhibition of Tumor Cell Growth," <i>Il Farmaco</i> 46:1311-1321 (1991).			
Fibach et al., "Phorbol Ester-Induced Adhesion of Murine Erythroleukemia Cells: Possible Involvement of Cellular Proteases," <i>Carcinogenesis</i> , 4:1395-1399, 1983.			
Fimognari et al., "Flow Cytometric Analysis of Genetic Damage, Effect on Cell Cycle Progression, and Apoptosis by Thiophanate-Methyl in Human Lymphocytes," <i>Environ. Mol. Mutagen.</i> 33:173-176 (1999).			
Ford et al., "Structural Features Determining Activity of Phenothiazines and Related Drugs for Inhibition of Cell Growth and Reversal of Multidrug Resistance," <i>Mol. Pharmacol.</i> 35:105-115 (1989).			
Fraser et al., "Endo-Exonuclease of Human Leukaemic Cells: Evidence for a Role in Apoptosis," <i>J. Cell Sci.</i> 109:2343-2360 (1996).			
Gambari et al., "DNA-Binding Activity and Biological effects of Aromatic Polyamidines," <i>Biochem. Pharmacol.</i> 47:599-610 (1994).			
Ganapathi et al., "Differential Effect of the Calmodulin Inhibitor Trifluoperazine (TFP) on Cellular Levels and Cytotoxic Activity of Daunorubicin (DAU), Aclacinomycin-A (ACM) and N-Trifluoroacetyladiamycin-14-Valerate (AD32) in Doxorubicin-Resistant Cells," <i>AACR Abstracts</i> 1328:335 (1984).			
Ganapathi et al., "Enhancement of Sensitivity to Adriamycin in Resistant P388 Leukemia by the Calmodulin Inhibitor Trifluoperazine," <i>Cancer Res.</i> 43:3696-3699 (1983).			
Ganapathi et al., "Factors Governing the Modulation of Vinca-Alkaloid Resistance in Doxorubicin-Resistant Cells by the Calmodulin Inhibitor Trifluoperazine," <i>Biochem. Pharmacol.</i> 35:673-678 (1986).			
Hait et al., "Antitumor and Toxic Effects of Combination Chemotherapy with Bleomycin and a Phenothiazine Anticalmodulin Agent," <i>J. Natl. Cancer Inst.</i> 80:246-250 (1988).			
Hait et al., "Calmodulin: A Potential Target for Cancer Chemotherapeutic Agents," <i>J. Clin. Oncol.</i> 4:994-1012 (1986).			
Hait et al., "Characteristics of the Cytotoxic Effects of the Phenothiazine Class of Calmodulin Antagonists," <i>Biochem. Pharmacol.</i> 34:3973-3978 (1985b).			
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. §1.98(b))		Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed Customer No.	50164/022002 10/617,424 Alexis Borisy et al. July 11, 2003 1614 August 29, 2005 21559
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)			
	Hait et al., "Inhibition of Growth of Leukemic Cells by Inhibitors of Calmodulin: Phenothiazines and Melittin," <i>Cancer Chemother. Pharmacol.</i> 14:202-205 (1985).		
	Hait et al., "Phase I Trial of Combined Therapy with Bleomycin and the Calmodulin Antagonist, Trifluoperazine," <i>Cancer Chemother. Pharmacol.</i> 23:358-362 (1989).		
	Herberich et al., "Synthesis of a Netropsin Conjugate of a Water-Soluble <i>epi</i> -Quinocarcin Analogue: the Importance of Stereochemistry at Nitrogen," <i>Bioorg. Med. Chem.</i> 8:523-532 (2000).		
	Huilgol et al., "Assessment of Chlorpromazine as Radiation Sensitizer and Protector," <i>Indian J. Cancer</i> 31:195-200 (1996).		
	Huilgol et al., "A Clinical Study to Assess Chlorpromazine as Hypoxic Cell Sensitizer in Head and Neck Cancer Treated with Conventional Radiation," <i>Indian J. Cancer</i> 35:97-100 (1998).		
	Ishikawa et al., "Exacerbation of Doxorubicin Lethality by Chlorpromazine in Mice," <i>Jpn. J. Pharmacol.</i> 55:291 (1991).		
	Ishikawa et al., "Protection Against Cisplatin and Doxorubicin Toxicity in BALB/C Mice by Chlorpromazine Hypothermia," <i>Research Communications in Psychology, Psychiatry, and Behavior</i> 16:93-96 (1991).		
	Jansen et al., "Chlorpromazine Down-Regulates Tumor Necrosis Factor-Alpha and Attenuates Experimental Multiple Organ Dysfunction Syndrome in Mice," <i>Crit. Care Med.</i> 26:1244-1250 (1998).		
	Jiang et al., "Transformation of Lupus-Inducing Drugs to Cytotoxic Products by Activated Neutrophils," <i>Science</i> 266:810-813 (1994).		
	Jones, "Successful Cancer Therapy with Promethazine: The Rationale," <i>Med. Hypotheses</i> 46:25-29 (1996).		
	Kim et al., "Effects of Calmodulin Antagonists and Anesthetics on the Skin Lesions Induced by 2-Chloroethylethyl Sulfide," <i>Eur. J. Pharmacol.</i> 313:107-114 (1996).		
	Kitamura et al., "Inhibition of Constitutive Nitric Oxide Synthase in the Brain by Pentamidine, a Calmodulin Antagonist," <i>Eur. J. Pharmacol.</i> 289:299-304 (1995).		
	Klemes et al., "Inhibition of Phorbol-Ester-Induced Adhesion of Differentiating Human Myeloid Leukemic Cells by pentamidine-Isethionate," <i>Differentiation</i> 27:141-145 (1984).		
	Kopac, M.J., "Section of Biology," <i>The New York Academy of Sciences</i> 5-10 (1945).		
	Kopac, M.J., "Some Cellular and Surface Chemical Aspects of Tumor Chemotherapy," in <i>Approaches to Tumor Chemotherapy</i> ed. F.R. Moulton, AAAS, Washington, D.C. pp. 27-57 (1947).		
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. §1.98(b))		Attorney Docket No. 50164/022002 Serial No. 10/617,424 Applicant Alexis Borisy et al. Filing Date July 11, 2003 Group 1614 IDS Filed August 29, 2005 Customer No. 21559
	Krishan et al., "Synergistic Effects of Prochlorperazine and Dipyridamole on the Cellular Retention and Cytotoxicity of Doxorubicin," <i>Clin. Cancer Res.</i> 6:1508-1517 (2000).	
	Kumar et al., "Inhibition of Protein Synthesis by Antagonists of Calmodulin in Ehrlich Ascites Tumor Cells," <i>Eur. J. Biochem.</i> 195:313-319 (1991).	
	Lee et al., "Inhibition of Growth of C6 Astrocytoma Cells by Inhibitors of Calmodulin," <i>Life Sci.</i> 36:347-354 (1985).	
	Libby et al., "Inhibition of Enzymes of Polyamine Back-Conversion by Pentamidine and Berenil," <i>Biochem. Pharmacol.</i> 44:830-832 (1992).	
	Luck et al., "Interaction of the Nonintercalative Antitumour Drugs SN-6999 and SN-18071 with DNA: Influence of Ligand Structure on the Binding Specificity," <i>J. Biomol. Struct. Dyn.</i> 4:1079-1094 (1987).	
	Mesa-Valle CM et al., "Action of New Organometallic Complexes Against <i>Leishmania donovani</i> ," <i>J. Antimicrob. Chemother.</i> 40:47-57 (1997).	
	Mesa-Valle et al., "In Vitro Action of Platinum (II) and Platinum (IV) Complexes on <i>Trypanosoma cruzi</i> and <i>Leishmania donovani</i> ," <i>Arzneimittelforschung</i> 39:838-842 (1989).	
	Mesa-Valle et al., "In Vitro and In Vivo Activity of Two Pt(IV) Salts Against <i>Leishmania donovani</i> ," <i>Pharmacology</i> 57:160-72 (1998).	
	Miller et al., "Clinical Modulation of Doxorubicin Resistance by the Calmodulin Inhibitor, Trifluoperazine: A Phase I/II Trial," <i>J. Clin. Oncol.</i> 6:880-888 (1988).	
	Mongiardo et al., "Pentamidine Salts," <i>Lancet</i> 2:108 (1989).	
	Naito et al., "Competitive Inhibition by Verapamil of ATP-Dependent High Affinity Vincristine Binding to the Plasma Membrane of Multidrug-resistant K562 Cells Without Calcium Ion Involvement," <i>Cancer Res.</i> 49:1452-1455 (1989).	
	Nastruzzi et al., "Differential Effects of Benzamidine Derivatives on the Expression of C-MYC and HLA-DR α Genes in a Human B-Lymphoid Tumor Cell Line," <i>Cancer Letters</i> 38:297-305 (1988).	
	Nastruzzi et al., "Inhibition of 'In Vitro' Tumor Cell Growth by Aromatic Polyamides Exhibiting Antiproteinase Activity," <i>Clin. Expl. Metastasis</i> 7:25-39 (1989).	
	Navas et al., "Structural Determinants of Putrescine Uptake Inhibition Produced by Cationic Diamidines in the Model of Trypanosomatid Crithidia Fasciculata," <i>Biol. Chem.</i> 377:833-836 (1996).	
	Nishimura et al., "A Serine Protease-Inhibitory Benzamidine Derivative Inhibits the Growth of Human Colon Carcinoma Cells," <i>Jpn. J. Cancer Res.</i> 83:723-728 (1992).	
EXAMINER		DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.		

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50164/022002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. §1.98(b))		Serial No.	10/617,424
		Applicant	Alexis Borisy et al.
		Filing Date	July 11, 2003
		Group	1614
		IDS Filed	August 29, 2005
		Customer No.	21559
	Nordenberg et al., "Effects of Psychotropic Drugs on Cell Proliferation and Differentiation," <i>Biochem. Pharmacol.</i> 58:1229-1236 (1999).		
	Nunn et al., "Sequence-Dependent Drug Binding to the Minor Groove of DNA: Crystal Structure of the DNA Dodecamer d(CGCAAATTTGCG) ₂ Complexed with Propamidine," <i>J. Med. Chem.</i> 38:2317-2325 (1995).		
	Ohtsuka et al., "Inhibitory Effect on LPS-Induced Tumor Necrosis Factor in Calves Treated with Chlorpromazine or Pentoxifylline," <i>J. Vet. Med. Sci.</i> 59:1075-1077 (1997).		
	Osei et al., "Diabetogenic Effect of Pentamidine," <i>Am. J. Med.</i> 77:41-46 (1984).		
	Palmer et al., "Correlation of Activity of Chlorpromazine and Respective Hydroxy, Dimethoxy and Sulphoxide Analogues on Dopamine, Muscarinic, Histamine and Calmodulin Sites of Action," <i>Xenobiotica</i> 18:277-289 (1988).		
	Pathak et al., "Pentamidine is an Inhibitor of PRL Phosphatases with Anticancer Activity," <i>Mol. Cancer Ther.</i> 1:1255-1264 (2002).		
	Perez et al., "Binding of Pt-Pentamidine to Nucleosomal DNA. Studies of the Antiproliferative Activity of the Drug Against Human Cancer Cells," <i>Chem Biol. Interact.</i> 89:61-72 (1993).		
	Perez et al., "DNA Binding Properties and Antileukemic (L1210) Activity of Pt-Pentamidine Complex," <i>Chem. Biol. Interact.</i> 77:341-355 (1991).		
	Prokopenko et al., "Effects of Haloperidol and Chlorpromazine on Smooth Muscle Contractility, Platelet Aggregation and Neuronal Calcium Current," <i>Gen. Physiol. Biophys.</i> 14:349-357 (1995).		
	Raderer et al., "Clinical Trials of Agents that Reverse Multidrug Resistance," <i>Cancer</i> 72:3553-3563 (1993).		
	Reddy et al., "Synthetic DNA Minor Groove-Binding Drugs," <i>Pharmacol. Ther.</i> 84:1-111 (1999).		
	Rosenthal et al., "Pentamidine: An inhibitor of Interleukin-1 that Acts Via a Post-Translational Event," <i>Toxicol. Appl. Pharmacol.</i> 107:555-561 (1991).		
	Sands et al., "Pentamidine: A Review," <i>Rev. Infect. Dis.</i> , 7:625-634, 1985.		
	Sansom et al., "Structural Studies on Bio-Active Compounds. Part XIV. Molecular Modelling of the Interactions Between Pentamidine and DNA," <i>Anti-Cancer Drug Design</i> , 5:243-248, 1990.		
	Schoenbach et al., "The Pharmacology, Mode of Action and Therapeutic Potentialities of Stilbamidine, Pentamidine, Propamidine and Other Aromatic Diamidines-A Review," <i>Medicine</i> , 27:327-377, 1948.		
	Shapiro et al., "Selective Cleavage of Kinetoplast DNA Minicircles Promoted by Antitrypanosomal Drugs", <i>Proc. Natl. Acad. Sci. USA</i> , 87:950-954 (1990).		
	Smid et al., "Radiotherapy, Combined with Simultaneous Chemotherapy with Mitomycin C and Bleomycin for Inoperable Head and Neck Cancer-Preliminary Report," <i>Int. J. Radiat. Oncol. Biol. Phys.</i> 32:769-775 (1995).		
EXAMINER	DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. §1.98(b))		Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed Customer No.	50164/022002 10/617,424 Alexis Borisy et al. July 11, 2003 1614 August 29, 2005 21559
	Snapper, I., "On the Influence of Stilbamidine Upon Multiple Myeloma," <i>Mt. Sinai J. Med.</i> 8:119-127 (1946).		
	Snapper, I., "Stilbamidine and Pentamidine in Multiple Myeloma," <i>J.A.M.A.</i> 133:157-161. (1947).		
	Syed et al., "Reversal of Vinblastine Transport by Chlorpromazine in Membrane Vesicles from Multidrug-Resistant Human CCRF-CEM Leukaemia Cells," <i>Brit. J. Cancer</i> 78:321-327 (1998).		
	Tidwell et al., "Analogues of 1,5-Bis(4-amidinophenoxy)pentane (Pentamidine) in the Treatment of Experimental Pneumocystis carinii Pneumonia," <i>J. Med. Chem.</i> 33:1252-1257 (1990).		
	Tsuruo et al., "Increased Accumulation of Vincristine and Adriamycin in Drug Resistant P388 Tumor Cells Following Incubation with Calcium Antagonist and Calmodulin Inhibitors," <i>Cancer Res.</i> 42:4730-4733 (1982).		
	Tsuruo et al., "Overcoming of Vincristine Resistance in P388 Leukemia in Vivo and In Vitro through Enhanced Cytotoxicity of Vincristine and Vinblastine by Verapamil," <i>Cancer Res.</i> 41:1967-1972 (1981).		
	Tsuruo et al., "Potentiation of Antitumor Agents by Calcium Channel Blockers with Special Reference to Cross Resistance Patterns," <i>Cancer Chemother. Pharmacol.</i> 15:16-19 (1985).		
	Turner et al., "The Mutagenic Properties of DNA Minor-Groove Binding Ligands," <i>Mutation Res.</i> 355:141-169 (1996).		
	Ueda et al., "Chlorpromazine Reduces Toxicity and Ca ²⁺ Uptake Induced by Amyloid Beta Protein (25-35) In Vitro," <i>Brain Res</i> 748:184-188 (1997).		
	Valeriote et al., "Synergistic Interaction of Anticancer Agents: A Cellular Perspective," <i>Cancer Chemother. Reports</i> 59:895-900 (1975).		
	Van Wauwe et al., "The Inhibitory Effect of Pentamidine on the Production of Chemotactic Cytokines by In Vitro Stimulated Human Blood Cells," <i>Inflamm. Res.</i> 45:357-363 (1996).		
	Von Hoff et al., "Use of Daunorubicin in Patients with Solid Tumors," <i>Semin. Oncol.</i> 11:23-27 (1984).		
	Waalkes et al., "Pentamidine: Clinical Pharmacologic Correlations in Man and Mice," <i>Clin. Pharmacol. Ther.</i> 11:505-512 (1970).		
	Wils et al., "Polarized Transport of Docetaxel and Vinblastine Mediated by P-Glycoprotein in Human Intestinal Epithelial Cell Monolayers," <i>Biochem. Pharmacol.</i> 48:1528-1530 (1994).		
	Zakotnik et al., "Concomitant Radiotherapy with Mitomycin C and Bleomycin Compared with Radiotherapy Alone in Inoperable Head and Neck Cancer: Final Report," <i>Int. J. Radiation Oncol. Biol. Phys.</i> 41:1121-1127 (1998).		
	Zakrzewska et al., "The Solvation Contribution to the Binding Energy of DNA with Non-Intercalating Antibiotics," <i>Nucleic Acids Res.</i> 12:6559-74 (1984).		
	National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results, NSC 620107 Experiment ID 9407SR53-57, 1994.		
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			